• 13 DE
• 14 EN

• 9 Home
• 10 Contact
• 11 Sitemap

• 7 Press
  • 7.1 Press Releases
    • 7.1.1 Company
      • 7.1.1.1 2000
      • 7.1.1.2 2001
      • 7.1.1.3 2002
      • 7.1.1.4 2003
      • 7.1.1.5 2004
      • 7.1.1.6 2005
      • 7.1.1.7 2006
      • 7.1.1.8 2007
      • 7.1.1.9 2008
    • 7.1.2 Health
  • 7.2 Photos & Logos

Recommendation of Approval for the Merz Botulinum Neurotoxin Typ A in European Countries

Frankfurt am Main, 20.07.2007

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) in London recommended the approval of the Merz- developed product Botulinum neurotoxin Type A. Merz is expecting approval in ten European countries within the next few months. The company already received approval in Denmark and Sweden.

The Botulinum neurotoxin Type A has already been approved in Germany since May 2005 for the indications blepharospasm (dystonia of the eyelid) and cervical dystonia of a predominantly rotational form (spasmodic torticollis, wryneck).
Outside of Europe, approval for these indications exists for Argentina and Mexico. In Argentina, the product is also approved for the temporary improvement of the glabellar frown lines in aesthetic dermatology.

"Botulinum neurotoxin Type A is a strategically important active ingredient for us," says Dr. Martin Zügel, CEO of Merz Pharmaceuticals. "We are pleased with the Committee's recommendation and will be intensifying our market launch activities and targeted promotions for success in these countries."

About Merz

Merz specializes in drugs for the treatment of neurological and psychiatric illnesses and is a leader in the field of Alzheimer's research. Merz developed Memantine, the world's first drug for the treatment of moderate to severe stages of Alzheimer's disease. Among drugs to combat Alzheimer's, Memantine is the second-largest in the world. Another area of competence at Merz is clinical and cosmetic dermatology.
Along with the pharmaceuticals market, Merz is active in the healthcare sector outside of pharmacies as well. With its tetesept® and Merz Spezial® brands, in German-speaking countries Merz is a leading provider of products for self-medication, dietary supplements, beauty and wellness.
A Merz subsidiary, Senator GmbH & Co. KGaA, is one of the leading manufacturers of high-quality promotional writing instruments worldwide.

The Merz Group employs 1,900 employees worldwide. The company achieved revenues of € 475 million in the 2005/06 fiscal year.

Download

Press Release

Your contact person:

Merz GmbH & Co. KGaA
Susanne Heiss
Corporate Communications
Eckenheimer Landstraße 100
60318 Frankfurt
Phone: +49 (0)69 / 15 03 - 411
Fax: +49 (0)69 / 15 03 - 581

E-Mail: susanne.heiss@merz.de

• 0.1 A-
• 0.2 A
• 0.3 A+
• 0.4 Print

Search

Search

Search

Login for Professionals

Login for Professionals

Merz DocCheck User Password

new user

German Websites

• Alzheimer´s
• Depression
• Dystonia
• Hair Loss
• Hyal-System
• Liver Disease
• Parkinson´s